Leqvio 284 mg solution for injection in pre filled syringe
*Company:
Novartis Ireland LimitedStatus:
UpdatedLegal Category:
Product subject to medical prescription which may be renewed (B)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 05 August 2025
File name
Leqvio_REG SPC_PF25-0123_30.07.2025_clean_IPHA.pdf
Reasons for updating
- Change to section 4.2 - Posology and method of administration
- Change to section 4.6 - Pregnancy and lactation
- Change to section 4.8 - Undesirable effects
- Change to section 5.1 - Pharmacodynamic properties
- Change to section 5.2 - Pharmacokinetic properties
- Change to section 6.1 - List of excipients
- Removal of Black Inverted Triangle
Legal category:Product subject to medical prescription which may be renewed (B)
Updated on 05 August 2025
File name
Leqvio_REG PIL_PF25-0123_30.07.2025_clean_IPHA.pdf
Reasons for updating
- Change to section 4 - how to report a side effect
- Change to section 6 - what the product contains
- Removal of Black Inverted Triangle
- Change to section 7 - Instructions for use
Updated on 08 August 2024
File name
Leqvio_REG SPC_PF22-0023_March 2022_Clean IPHA.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to medical prescription which may be renewed (B)
Free text change information supplied by the pharmaceutical company
New entry on medicines.ie
Updated on 08 August 2024
File name
Leqvio PFS REG PIL PF24-085 April 2024 clean IPHA.pdf
Reasons for updating
- New PIL for new product
Free text change information supplied by the pharmaceutical company
New entry to medicines.ie
Novartis Ireland Limited
Address:
Vista Building, Elm Park Business Park, Merrion Road, Dublin 4, IrelandMedical Information E-mail:
medinfo.dublin@novartis.comTelephone:
+353 1 2601255Fax:
+353 1 2601263